| scholarly article | Q13442814 |
| P50 | author | Jeffrey Morin | Q61142628 |
| Joseph F Nabhan | Q81346655 | ||
| Renea Gooch | Q83272755 | ||
| P2093 | author name string | Christine E Bulawa | |
| Timothy P LaBranche | |||
| Kristy M Wood | |||
| Surya Bhamidipaty | |||
| Varada P Rao | |||
| Braydon C Guild | |||
| Fazli Bozal | |||
| P2860 | cites work | Pathology and pathogenesis of sensory neuropathy in Friedreich's ataxia | Q83912301 |
| The dorsal root ganglion in Friedreich's ataxia | Q84511482 | ||
| Business: The billion-dollar biotech | Q85290452 | ||
| mRNA-based therapeutics--developing a new class of drugs | Q38252360 | ||
| Current perspectives on intrathecal drug delivery | Q38268090 | ||
| Mammalian iron-sulphur proteins: novel insights into biogenesis and function | Q38271496 | ||
| Spectrum of neuropathophysiology in spinal muscular atrophy type I | Q39084725 | ||
| Transcription activator-like effector proteins induce the expression of the frataxin gene | Q39348028 | ||
| A Potential New Therapeutic Approach for Friedreich Ataxia: Induction of Frataxin Expression With TALE Proteins | Q39793086 | ||
| Comparative Immunogenicity of a Cytotoxic T Cell Epitope Delivered by Penetratin and TAT Cell Penetrating Peptides. | Q40654151 | ||
| Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich's ataxia | Q42226636 | ||
| Expression of therapeutic proteins after delivery of chemically modified mRNA in mice | Q45866149 | ||
| Human BAC-mediated rescue of the Friedreich ataxia knockout mutation in transgenic mice | Q45875661 | ||
| Iron-dependent regulation of frataxin expression: implications for treatment of Friedreich ataxia | Q24323371 | ||
| Cardiomyopathy in Friedreich ataxia: clinical findings and research | Q26827933 | ||
| Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes | Q28249379 | ||
| Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion | Q28275699 | ||
| Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits | Q28505173 | ||
| Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction | Q30580723 | ||
| The in vivo mitochondrial two-step maturation of human frataxin. | Q33363024 | ||
| Mammalian frataxin: an essential function for cellular viability through an interaction with a preformed ISCU/NFS1/ISD11 iron-sulfur assembly complex. | Q33813547 | ||
| Cellular, molecular and functional characterisation of YAC transgenic mouse models of Friedreich ataxia | Q34150158 | ||
| A rapid, noninvasive immunoassay for frataxin: Utility in assessment of Friedreich ataxia | Q34376985 | ||
| Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study. | Q34418695 | ||
| Human frataxin activates Fe-S cluster biosynthesis by facilitating sulfur transfer chemistry | Q34434217 | ||
| Repeat expansion affects both transcription initiation and elongation in friedreich ataxia cells | Q34575655 | ||
| R-loops associated with triplet repeat expansions promote gene silencing in Friedreich ataxia and fragile X syndrome. | Q35160930 | ||
| Epigenetic therapy for Friedreich ataxia | Q35180607 | ||
| An AAV9 coding for frataxin clearly improved the symptoms and prolonged the life of Friedreich ataxia mouse models | Q35184184 | ||
| Biodistribution of small interfering RNA at the organ and cellular levels after lipid nanoparticle-mediated delivery | Q35681765 | ||
| A TAT-frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich's ataxia mouse model | Q35770976 | ||
| Frataxin levels in peripheral tissue in Friedreich ataxia | Q36010435 | ||
| Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes | Q36218294 | ||
| Nikolaus Friedreich and degenerative atrophy of the dorsal columns of the spinal cord | Q37040757 | ||
| Improving the endosomal escape of cell-penetrating peptides and their cargos: strategies and challenges | Q37277330 | ||
| The pathogenesis of Friedreich ataxia and the structure and function of frataxin | Q37414028 | ||
| Friedreich ataxia: metal dysmetabolism in dorsal root ganglia | Q37485501 | ||
| The dorsal root ganglion under attack: the acquired sensory ganglionopathies | Q37811641 | ||
| Design of multifunctional non-viral gene vectors to overcome physiological barriers: dilemmas and strategies | Q37907456 | ||
| Animal and cellular models of Friedreich ataxia. | Q38121944 | ||
| Cardiomyopathy of Friedreich ataxia | Q38121946 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | nanoparticle | Q61231 |
| Friedreich ataxia | Q913856 | ||
| P304 | page(s) | 20019 | |
| P577 | publication date | 2016-02-17 | |
| P1433 | published in | Scientific Reports | Q2261792 |
| P1476 | title | Intrathecal delivery of frataxin mRNA encapsulated in lipid nanoparticles to dorsal root ganglia as a potential therapeutic for Friedreich's ataxia | |
| P478 | volume | 6 |
| Q52589409 | A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates. |
| Q63246454 | Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery |
| Q89825189 | Developments in the treatment of Fabry disease |
| Q56700247 | Emerging therapeutics for the treatment of Friedreich’s ataxia |
| Q92706998 | Endocytic Profiling of Cancer Cell Models Reveals Critical Factors Influencing LNP-Mediated mRNA Delivery and Protein Expression |
| Q92420379 | Improved Efficacy in a Fabry Disease Model Using a Systemic mRNA Liver Depot System as Compared to Enzyme Replacement Therapy |
| Q90650808 | Intrathecal Administration of Nanoclusters for Protecting Neurons against Oxidative Stress in Cerebral Ischemia/Reperfusion Injury |
| Q90261644 | Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells |
| Q39027005 | Modified mRNA as a therapeutic tool to induce cardiac regeneration in ischemic heart disease |
| Q63246865 | Nanoscale platforms for messenger RNA delivery |
| Q41652242 | New Reasons to Pursue the Therapeutic Potential of Synthetic Nucleic Acids for Neurological Diseases |
| Q47793738 | Overexpression of Drosophila frataxin triggers cell death in an iron-dependent manner. |
| Q39445743 | Pharmacological therapeutics in Friedreich ataxia: the present state |
| Q45873314 | Sustained FXN expression in dorsal root ganglia from a nonreplicative genomic HSV-1 vector |
| Q64039292 | Targeted Oligonucleotides for Treating Neurodegenerative Tandem Repeat Diseases |
| Q92578310 | Therapeutic Prospects for Friedreich's Ataxia |
| Q95641937 | Topical Delivery of Four Neuroprotective Ingredients by Ethosome-Gel: Synergistic Combination for Treatment of Oxaliplatin-Induced Peripheral Neuropathy |
| Q64113665 | Treatment of Intervertebral Disk Disease by the Administration of mRNA Encoding a Cartilage-Anabolic Transcription Factor |
| Q91900980 | mRNA as a Novel Treatment Strategy for Hereditary Spastic Paraplegia Type 5 |
| Q58605707 | mRNA as novel technology for passive immunotherapy |
| Q92455760 | mRNA: A Novel Avenue to Antibody Therapy? |
Search more.